Table 4.

Summary of outcome and follow-up of children with refAML and relAML

	refAML (n = 16)	relAML (n = 62)
Postreinduction CR rate	n = 5 (33%)	n = 45 (77%)
First/second relapse	n = 2/5 (0.3 and 26 months)*	n = 14/45 (31%) 16.4 months (range 0.6–16.4)**
Survival in CR1/CR2	n = 3/5 33.2 months (range 17.8–34.2)**	n = 16/45 (35%) 30.4 months (range 0.03–87.6)**
pDFS	2 years, 0.533 ±0.248	5 years, 0.305 ±0.07
pEFS	3 years, 0.167 ±0.093	5 years, 0.177 ±0.05
pOS	3 years, 0.25 ±0.108 median follow-up 37.3 months (range 17.8–37.4)	5 years, 0.164 ±0.079 median follow-up 19.8 months (range 0.6–88.3)

^*Time from remission

^**Median time from remission